FRIDAY, March 21, 2025 -- In a clinical guideline issued by the American College of Physicians (ACP) and published online March 18 in the

2025年3月21日，星期五——美国医师学会（ACP）发布了一项临床指南，并于3月18日在线发表在

Annals of Internal Medicine,

内科医学年鉴，

recommendations are presented for the pharmacologic treatment of acute episodic migraine headache in the outpatient setting.

以下是门诊急性发作性偏头痛药物治疗的建议。

Amir Qaseem, M.D., Ph.D., from the ACP in Philadelphia, and colleagues examined the comparative benefits and harms of pharmacologic treatments of acute episodic migraine headache, patients' values and preferences, and economic evidence relating to the treatments. The guidelines were designed for physicians and other clinicians and related to adults with acute episodic migraine headache (defined as one to 14 headache days per month) managed in outpatient settings..

费城ACP的Amir Qaseem医学博士及其同事比较了急性发作性偏头痛药物治疗的益处与危害、患者的价值观和偏好，以及与治疗相关的经济证据。该指南专为医生及其他临床医生设计，适用于在门诊环境中管理的成人急性发作性偏头痛（定义为每月1至14天头痛）。

The authors presented two recommendations. For nonpregnant adults who do not respond adequately to a nonsteroidal anti-inflammatory drug, ACP recommends the addition of a triptan to treat moderate-to-severe acute episodic migraine headache in outpatient settings (strong recommendation; moderate-certainty evidence).

作者提出了两项建议。对于使用非甾体抗炎药效果不佳的非孕妇，ACP 建议添加曲普坦类药物，用于在门诊治疗中重度急性发作性偏头痛（强烈建议；中等确定性证据）。

For nonpregnant adults who do not respond adequately to acetaminophen, ACP suggests that clinicians add a triptan to treat moderate-to-severe acute episodic migraine headache in outpatient settings (conditional recommendation; low-certainty evidence)..

对于非孕期成人，如果对乙酰氨基酚反应不佳，ACP 建议临床医生在外门诊治疗中添加曲普坦类药物来治疗中至重度的急性偶发性偏头痛（有条件推荐；证据确定性低）。

'There is a critical need for funding agencies, such as the Patient-Centered Outcomes Research Institute or National Institute of Neurological Disorders and Stroke, to support well-designed, comparative effectiveness trials of newer medications to treat moderate-to-severe episodic migraine compared with the combination of a triptan and an NSAID or acetaminophen,' the authors write..

“作者写道，像以患者为中心的结果研究所或国家神经疾病和中风研究所这样的资助机构，迫切需要支持设计良好的比较有效性试验，针对治疗中度至重度发作性偏头痛的新药与曲普坦类药物和非甾体抗炎药或对乙酰氨基酚的组合进行比较。”

Abstract/Full Text (subscription or payment may be required)

摘要/全文（可能需要订阅或付费）

Editorial (subscription or payment may be required)

社论（可能需要订阅或付费）

Whatever your topic of interest,

无论你感兴趣的话题是什么，

subscribe to our newsletters

订阅我们的新闻通讯

to get the best of Drugs.com in your inbox.

获取 Drugs.com 的最佳内容到您的收件箱。